Mindfulness Intervention for Dysautonomia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
UCLA Health, Los Angeles, CADysautonomia+1 MoreMindfulness - Mindful Awareness Practices ( MAPs) - Other
Eligibility
18 - 54
Female
What conditions do you have?
Select

Study Summary

This trial will explore if mindfulness can help people with COVID-19 symptoms over a 6-week course.

Eligible Conditions
  • Dysautonomia
  • Long COVID

Treatment Effectiveness

Study Objectives

4 Primary · 8 Secondary · Reporting Duration: Baseline / Pre Intervention(1-2 weeks prior to intervention), Post Intervention (1-2 weeks post intervention completion); 4 weeks post intervention

Week 2
Change from baseline in Active Stand Test of hemodynamic symptom parameters, exercise tolerance.
Change from baseline in the composite autonomic symptom score COMPASS-31 for autonomic symptoms
Change from baseline of Six Minute Walk in hemodynamic parameters, exercise tolerance
Week 4
Change from baseline in mean score in Health-Related Quality of Life (QOL) SF-20
Change from baseline in mean scores of CD-RISC 10 - Connor Davidson Resilience Scale.
Fatigue
Change from baseline in mean scores of GAD7- Generalized Anxiety Disorder
Change from baseline in mean scores of IES-R - event-related distress scale
Depressive Symptoms
Change from baseline in mean scores of PSS- Perceived Stress Scale.
Change from baseline in mean scores of the ISI - The Insomnia Severity Index
Change from baseline in mean scores of well-being from MHC-SF-The Mental Health Continuum Short Form

Trial Safety

Trial Design

1 Treatment Group

Mindfulness Intervention
1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Mindfulness Intervention · No Placebo Group · N/A

Mindfulness Intervention
Other
Experimental Group · 1 Intervention: Mindfulness - Mindful Awareness Practices ( MAPs) · Intervention Types: Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline / pre intervention(1-2 weeks prior to intervention), post intervention (1-2 weeks post intervention completion); 4 weeks post intervention

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor
1,423 Previous Clinical Trials
6,773,584 Total Patients Enrolled
Jeffrey J. Hsu, MD, PhDPrincipal InvestigatorUniversity of California, Los Angeles

Eligibility Criteria

Age 18 - 54 · Female Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Frequently Asked Questions

Is access to this medical investigation restricted to persons aged 55 and over?

"The age range of the desired participants for this trial is 18 years or older to 54 years old." - Anonymous Online Contributor

Unverified Answer

What criteria must an individual meet to be eligible for this research?

"To be eligible for this research, applicants must have dysautonomia and fall between 18-54 years of age. Approximately 30 participants are being accepted into the trial." - Anonymous Online Contributor

Unverified Answer

Is recruitment still underway for this experimental project?

"Yes, the information on clinicaltrials.gov verifies that this medical trial is currently recruiting participants. It was first posted to the website on February 1st 2023 and recently revised on January 20th 23rd. The study requires 30 individuals at a single location." - Anonymous Online Contributor

Unverified Answer

How many participants are enrolled in this trial?

"Indeed, according to clinicaltrials.gov, this medical study is soliciting participants as of now. It was initially posted on February 1st 2023 and has been recently updated on January 20th 2023. 30 individuals are sought from a single research institution." - Anonymous Online Contributor

Unverified Answer

What are the ultimate objectives of this research endeavor?

"The primary objective of the study, which will be evaluated over a pre-intervention and post-intervention timeline, is to assess changes in hemodynamic symptom parameters and exercise tolerance. Secondary outcomes include assessing Perceived Stress Scale (PSS) scores as well as Impact of Event Scale -Revised (IES-R) ratings that measure event related distress levels. Lastly, Fatigue Symptom Inventory (FSI) evaluations are used to gain insight into how fatigue affects quality of life." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.